Results 61 to 70 of about 37,073 (238)

2H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as novel selective fibroblast growth factor receptor 2 (FGFR2) inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry
Although FGFR2 is a well-validated oncogenic target, no selective FGFR2 inhibitors have been approved for clinical use. In this study, we report the discovery of 2H-pyrazolo[3,4-d]pyrimidin-4-amine derivative as novel, irreversible FGFR2 inhibitors.
Pinglian Wu, Zhaodi Tian, Weizhong Shen, Qiuju Xun, Yuan Tian, Huiqiong Li, Bowen Yang, Shaohua Chang, Weixue Huang, Zhen Wang, Ke Ding, Dawei Ma   +11 more
doaj   +1 more source

Influence of FGF4 and BMP4 on FGFR2 dynamics during the segregation of epiblast and primitive endoderm cells in the pre-implantation mouse embryo.

PLoS ONE, 2023
Specification of the epiblast (EPI) and primitive endoderm (PE) in the mouse embryo involves fibroblast growth factor (FGF) signaling through the RAS/MAP kinase pathway.
Marcelo D Goissis, Brian Bradshaw, Eszter Posfai, Janet Rossant   +3 more
doaj   +1 more source

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

New England Journal of Medicine, 2023
Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibitor, has been shown to have both antitumor activity in patients with FGFR-altered tumors and strong preclinical ...
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-Josef Klümpen, Heung-Moon Chang, Li-Tzong Chen, Josep Tabernero, Do-Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Robert S. Epstein, Abdel-Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John A. Bridgewater   +29 more
openaire   +2 more sources

Multi‐Tissue Crosstalk Regulating Meniscus Healing Under Inflammation and Physiological Loading

Advanced Science, EarlyView.
Using a novel Meniscus‐on‐a‐chip (MoC) model integrated with a meniscus‐specific bioreactor, this study investigated the roles of multi‐tissue crosstalk that regulates injury, healing, and degeneration of the meniscus injury under inflammation and pathophysiological loading.
Hun Jin Jeong, Elen Zhu, Min Seo Kang, Ming Wang, Sam Comito, Chang H. Lee   +5 more
wiley   +1 more source

GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

, 2010
Dysregulated fibroblast growth factor (FGF) signaling has been implicated in the pathogenesis of human cancers. Aberrant activation of FGF receptor 2 (FGFR2) signaling, through overexpression of FGFR2 and/or its ligands, mutations, and receptor ...
Laura L. Poling, Ting Chen, Solly Weiler, Nhi Y. Vo, Zhigang Weng, Kristan Meetze, Lorena Lerner, Jinwei Jiang, William M. Winston, Jeno Gyuris, Ailin Bai, Nesreen S. Ismail, Elizabeth K. Mazsa, Sriram Kollipara   +13 more
core   +1 more source

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting

Cancer Management and Research, 2021
Massimiliano Salati,1,2 Francesco Caputo,1 Cinzia Baldessari,1 Pietro Carotenuto,3 Marco Messina,4 Stefania Caramaschi,5 Massimo Dominici,1 Luca Reggiani Bonetti5 1Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; 2PhD ...
Salati M, Caputo F, Baldessari C, Carotenuto P, Messina M, Caramaschi S, Dominici M, Bonetti LR   +7 more
doaj  

A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers

Frontiers in Oncology, 2021
Background: Fibroblast growth factor receptor 2 (FGFR2) is frequently altered in tumors and one of the top therapeutic targets in cholangiocarcinoma (CHOL) with FGFR2 fusions. Although there have been several studies on individual tumors, a comprehensive
Juanni Li, Kuan Hu, Jinzhou Huang, Lei Zhou, Yuanliang Yan, Yuanliang Yan, Zhijie Xu   +6 more
doaj   +1 more source

The Characteristics of Tumor Microenvironment by the Single Cell Profile in Endometrial Cancer of no Specific Molecular Profile (NSMP) Subtype

Advanced Science, EarlyView.
A subset of tumor‐associated macrophages (TAMs) characterized by SPP1 expression is discovered, which may remodel the tumor microenvironment by potentially promoting CD4+ T cell stress and maintaining epithelial cell stemness through SPP1‐CD44, thereby potentially contributing to the proliferation and migration of tumor cells, which has been verified ...
Xinhui Yuan, Zhengyao Zhai, Chuyu Jing, Wei Zhang, Wenjuan Tian, Yulan Ren   +5 more
wiley   +1 more source

Novel FGFR2 fusion genes in SNU-16 gastric cancer cell line

, 2013
Fusion genes in SNU-16 gastric cancer cell line found using using FusionCatcher and RNA-seq data. The novel FGFR2 fusion genes (i.e.FGFR2-PPAPDC1A, FGFR2-MYC, FGFR2-MUC, FGFR2-PDHX, CD44-FGFR2) were found in SNU-16 cell line.
Daniel Nicorici (101429)
core   +1 more source

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. [PDF]

PLoS ONE, 2010
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all will develop resistance and relapse. Gene expression analysis of NSCLC cell lines treated with the EGFR TKI, gefitinib, revealed increased levels of FGFR2 ...
Kathryn E Ware, Marianne E Marshall, Lydia R Heasley, Lindsay Marek, Trista K Hinz, Paula Hercule, Barbara A Helfrich, Robert C Doebele, Lynn E Heasley   +8 more
doaj   +1 more source